BT8009 monotherapy in enfortumab vedotin (EV)-naive patients (pts) with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1

被引：1
|
作者：
Reig Torras, O. [1 ]
Crouzet, L. [2 ]
Necchi, A. [3 ,4 ]
Baldini, C. [5 ]
Lostes Bardaji, M. J. [6 ,7 ]
Doger de Speville, B. [8 ]
Italiano, A. [9 ,10 ]
Verlingue, L. [11 ]
Boni, V. [12 ]
Carter, L. [13 ,14 ]
Duran, I. [15 ]
Garmezy, B. [16 ]
Galsky, M. D. [17 ]
Falchook, G. S. [18 ]
DeMars, L. [19 ]
Josephs, K. [20 ]
Xu, C. [21 ]
Bader, J. [22 ]
Fontana, E. [23 ]
机构：
[1] Hosp Clin Barcelona, Dept Med Oncol, Barcelona, Spain
[2] Ctr Eugene Marquis, UNICANCER, Rennes, France
[3] Univ Vita Salute San Raffaele, Dept Med Oncol, Milan, Italy
[4] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy
[5] Gustave Roussy Canc Campus, Drug Dev Dept DITEP, Villejuif, France
[6] Vall DHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[7] Vall dHebron Inst Oncol, Oncol Dept, Barcelona, Spain
[8] START Madrid FJD Hosp Univ Fdn Jimenez Diaz, Start Madrid Phase Unit 1, Madrid, Spain
[9] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France
[10] Univ Bordeaux, Bordeaux, France
[11] Ctr Leon Berard, Phase Clin Unit 1, Lyon, France
[12] NEXT Madrid, Univers Hosp Quiron Salud Madrid, Madrid, Spain
[13] Univ Manchester, Med Oncol, Manchester, Lancs, England
[14] Christie NHS Fdn Trust, Manchester, Lancs, England
[15] Hosp Univ Marques de Valdecilla IDIVAL, Dept Despacho 271, Santander, Spain
[16] Sarah Cannon Res Inst, Med Oncol, Nashville, TN USA
[17] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA
[18] HealthONE, Sarah Cannon Res Inst, Med Oncol, Denver, CO USA
[19] Bicycle Therapeut, Clin Dev, Cambridge, MA USA
[20] Bicycle Therapeut, Clin Sci, Cambridge, MA USA
[21] Bicycle Therapeut, Biostat, Cambridge, MA USA
[22] Bicycle Therapeut, Quantitat Pharmacol, Cambridge, MA USA
[23] Sarah Cannon Res Inst UK, Drug Dev, London, England
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.718
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
652P
引用
收藏
页码：S515 / S516
页数：2
相关论文
共 50 条
  • [1] Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).
    Rosenberg, Jonathan E.
    Sridhar, Srikala S.
    Zhang, Jingsong
    Smith, David C.
    Ruether, Joseph D.
    Flaig, Thomas W.
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Plimack, Elizabeth R.
    Sangha, Randeep S.
    Heath, Elisabeth I.
    Merchan, Jaime R.
    Quinn, David I.
    Srinivas, Sandy
    Milowsky, Matthew I.
    Wu, Chunzhang
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] Association of enfortumab vedotin (EV) toxicity with baseline parameters and clinical outcomes in patients (pts) with metastatic urothelial carcinoma (mUC)
    Semaan, Karl
    El Zarif, Talal
    Saliby, Renee Maria
    Eid, Marc
    Saad, Eddy
    Labaki, Chris
    Kwak, Lucia
    Kaymakcalan, Marina D.
    Baca, Sylvan
    Berg, Stephanie A.
    Xie, Wanling
    Mantia, Charlene
    Choueiri, Toni K.
    McGregor, Bradley Alexander
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] Clinical outcomes of patients with metastatic urothelial carcinoma (mUC) discontinuing enfortumab vedotin (EV) monotherapy (mono) without disease progression
    Sternschuss, M.
    Whiting, K.
    Teo, M. Y.
    Bajorin, D.
    Kotecha, R.
    Laccetti, A. L.
    Xiao, H.
    Feld, E.
    McHugh, D. J.
    Keegan, N.
    Apollo, A.
    Owens, C.
    Funt, S. A.
    Shah, N. J.
    Iyer, G.
    Aggen, D. H.
    Ostrovnaya, I.
    Rosenberg, J. E.
    ANNALS OF ONCOLOGY, 2024, 35 : S1157 - S1158
  • [4] Association of changes in albumin levels with survival and toxicities in patients (pts) with metastatic urothelial carcinoma (mUC) receiving enfortumab vedotin (EV).
    El Zarif, Talal
    Bin Riaz, Irbaz
    Adib, Elio
    Freeman, Dory
    Madueke, Ikenna C.
    Davidsohn, Matthew
    McClure, Heather
    Nuzzo, Pier Vitale
    McGregor, Bradley Alexander
    Mantia, Charlene
    Ravi, Praful
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Clinical efficacy analysis of patients (pts) with HER-2 expressing metastatic urothelial carcinoma (mUC) treated with enfortumab vedotin (EV)
    Jiang, Cindy
    Alhalabi, Omar
    Haro-Silerio, Jaime
    Qiao, Wei
    Shah, Amishi Yogesh
    Siefker-Radtke, Arlene O.
    Gao, Jianjun
    Goswami, Sangeeta
    Alva, Ajjai Shivaram
    Koshkin, Vadim S.
    Guo, Charles
    Campbell, Matthew T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Outcomes of patients (pts) with metastatic urothelial carcinoma (mUC) following discontinuation of enfortumab-vedotin (EV): Emergence of a new unmet need.
    Curran, Catherine
    Pond, Gregory Russell
    Kazakova, Vera
    Grivas, Petros
    Diamantopoulos, Leonidas Nikolaos
    Alva, Ajjai Shivaram
    Su, Christopher
    Jain, Rohit K.
    Tandon, Ankita
    Zhang, Jingsong
    Necchi, Andrea
    Marandino, Laura
    Merchan, Jaime R.
    Plastini, Trisha M.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] Evorpacept plus enfortumab vedotin in patients (Pts) with locally advanced or metastatic urothelial carcinoma (la/mUC): Phase 1a dose escalation results
    Funt, Samuel A.
    Grivas, Petros
    Gao, Xin
    Vaena, Daniel A.
    Zhang, Tian
    Milowsky, Matthew I.
    Rao, Mayank
    Liu, Harry
    Tipton, Kimberly
    An, Grace
    Jin, Feng
    Forgie, Alison J.
    Randolph, Sophia
    Tsiatis, Athanasios C.
    Jain, Rohit K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).
    Khan, Mohammed Ateeb
    Szabados, Bernadett
    Choy, Julia
    Jackson-Spence, Francesca
    Powles, Thomas
    Castellano, Daniel
    Valderrama, Begona P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.
    Petrylak, Daniel Peter
    Smith, David C.
    Flaig, Thomas W.
    Zhang, Jingsong
    Sridhar, Srikala S.
    Ruether, Joseph D.
    Plimack, Elizabeth R.
    Merchan, Jaime R.
    Quinn, David I.
    Kilari, Deepak
    Srinivas, Sandy
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Milowsky, Matthew I.
    Galsky, Matt D.
    Spira, Alexander I.
    Gartner, Elaina M.
    Wu, Chunzhang
    Melhem-Bertrandt, Amal
    Rosenberg, Jonathan E.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [10] Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
    Rosenberg, Jonathan E.
    Sridhar, Srikala S.
    Zhang, Jingsong
    Smith, David C.
    Ruether, Joseph D.
    Flaig, Thomas W.
    Baranda, Joaquina Celebre
    Lang, Joshua Michael
    Plimack, Elizabeth R.
    Sangha, Randeep S.
    Heath, Elisabeth I.
    Merchan, Jaime R.
    Quinn, David I.
    Srinivas, Sandy
    Milowsky, Matthew I.
    Wu, Chunzhang
    Gartner, Elaina M.
    Melhem-Bertrandt, Amal
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
12345